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ORGAN TRANSPLANTATION AND THE LIVER TOLERANCE EFFECT: 
HISTORY, MECHANISMS, AND POTENTIAL IMPLICATIONS FOR THE 
FUTURE OF TRANSPLANT CARE 
ANDREW J. KIM 
 
ABSTRACT 
 
Chronic immune insult and immunosuppressant-related toxicities have remained 
an enduring challenge in organ transplantation. Long-term survival of transplant patients 
has improved marginally in recent decades due to these challenges. To circumvent these 
issues, transplant investigators have researched immune tolerance mechanisms that 
demonstrate potential to induce immunosuppression and rejection-free survival in the 
clinic. One mechanism in particular, the liver tolerance effect, has already demonstrated 
this experimentally and clinically. Liver transplants in experimental models and human 
patients have exhibited the ability to become spontaneously accepted without being 
rejected by the recipient’s immune system. Research in recent decades has revealed that 
the liver parenchymal and non-parenchymal cell populations harbor potent 
immunomodulatory properties. In the context of liver transplantation, it has been found 
that two cell populations in particular, the mesenchyme-derived liver sinusoidal 
endothelial cells and hepatic stellate cells, mediate the induction of liver transplant 
tolerance through a mechanism known as mesenchyme-mediated immune control.   
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INTRODUCTION 
 
The modern history of organ transplantation, spanning over the last century, has 
been woefully characterized by extensive trial and error, but this has allowed the 
transplant patients of today to enjoy a vast improvement in short-term survival and 
quality of life. However, in recent decades, the long-term survival of patients has shown 
minimal improvement due to progressive donor organ dysfunction caused either by 
chronic immune insult or immunosuppressant-mediated side effects. For this reason 
transplant investigators have been pursuing an understanding of immune tolerance 
mechanisms. Of particular interest has been the liver tolerance effect, a strange 
immunological phenomenon first observed in pigs in 1969 in which liver transplants were 
spontaneously accepted without the need for immunosuppressant drugs.  
The following thesis is divided into two parts. The first part of this thesis––the 
following subsections of this introduction––will provide historical context for organ 
transplantation with respect to the development of immunosuppression as well as the 
events that sparked the discovery of immune tolerance mechanisms, including the liver 
tolerance effect. This will set the stage for the second part of the thesis, which will focus 
on describing the current evidence gathered on specific cellular mediators of liver 
tolerance as well as a discussion of a relatively recent theory that attempts to explain 
spontaneous liver transplant acceptance and how the implications of this theory may 
affect the future of transplant care.  
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The Path to Immunosuppression: The Good, The Bad, and The Ugly 
December 23, 1954 marked a watershed moment in the history of organ 
transplantation. At 23-years-old, Ronald Herrick donated one of his kidneys to his 
identical twin brother, Richard, and a surgical team led by Joseph Murray at Peter Bent 
Brigham Hospital (Figure 1) would go on to perform the world’s first successful human 
organ transplant procedure that resulted in long-term survival (Guild, Harrison, Merrill, 
& Murray, 1955). Decades-long research and experimentation elaborating upon Alexis 
Carrel’s pioneering techniques in vascular anastomosis made it technically possible for 
Murray’s team to perform such an operation (Annales de la Société de médecine de Lyon, 
1902; Doyle, Lechler, & Turka, 2004; Sade, 2005). Although the clinical transplantation 
of other organs proceeded to success at different rates, after 1954 it no longer seemed to 
be a question of whether organ transplantation could be done in humans, but rather how 
effective would it be as a treatment for end-stage organ failure and other indications 
(Starzl, 2000).  
The nature of the operation performed by Murray and his team was reflective of 
the deeper troubles that confounded early transplant clinicians and investigators. In this 
unique case the donor and recipient were genetically identical individuals—this is known 
as syngeneic transplantation, whereas transplantation involving two genetically disparate 
individuals is allogeneic; the caveat in both situations being that the donor and recipient 
are members of the same species. During the first several decades of the 1900’s, the 
prevailing wisdom from animal experimentation was that autotransplantation 
(transplantation within the same individual) and syngeneic transplantation resulted in 
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organ or graft acceptance, while allogeneic transplantation resulted in graft rejection 
(Doyle et al., 2004; Sade, 2005). However, it was hardly understood why this was the 
case or how rejection was even mediated, for that matter.  
 
Figure 1. The Herrick twins and the first successful human organ transplant 
procedure resulting in long-term survival. In the photograph on the left, Richard (left) 
and Ronald (right) sit together during a press conference after their historical renal 
transplant procedure. In the photograph on the right, Dr. Joseph Murray is seen operating 
on one of the twins at Peter Bent Brigham Hospital (currently known as Brigham and 
Women’s Hospital) in Boston. Photos taken from the Associated Press Image Archives 
and Brigham & Women’s Hospital Newsroom.  
 
The nature of graft rejection remained largely a mystery until the 1940’s when 
studies by Peter Medawar suggested an immune mechanism of graft rejection. Medawar 
had performed 625 skin grafting operations in outbred rabbits, which distinctly 
demonstrated that rejection was mediated by a recipient’s own immune cells (Medawar, 
1944, 1945). Allogeneic skin grafts were marked by extensive lymphocytic infiltration 
and other rejection characteristics, whereas autografted skin remained intact and healed 
with no evidence of major immune involvement. Medawar also observed that larger 
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allogeneic skin grafts were rejected faster than smaller ones and that repeated 
transplantation of allogeneic grafts from the same donor resulted in faster rejection as 
well. In regards to the observation on graft size, the accelerated kinetics of rejection in 
the larger skin grafts appeared to be counterintuitive, as one might expect that a larger 
graft would take a longer time to destroy. However, this made sense from an immune 
perspective, as a large foreign “threat” would trigger a proportionately sized response by 
the immune system, thereby destroying the graft faster than one might expect (Davis, 
2014). The observation of accelerated rejection in repeated transplantation also seemed to 
confirm immune involvement since it mimicked a memory phenotype that was 
commonly observed in the immune system’s response to repeatedly encountered 
pathogens (Davis, 2014). From this evidence it was clear that organ rejection in 
allogeneic transplantation was mediated by a recipient’s immune system, and further, in 
the special circumstances of autotransplantation or syngeneic transplantation, the genetic 
identity of the transplanted tissue conferred protection from rejection.  
Murray’s success in 1954 was therefore heavily dependent on the genetic identify 
of the Herrick twins. As most individuals lack an identical twin or duplicate organs, it 
was clear that the future of organ transplantation in humans would have to heavily rely on 
allogeneic grafts (i.e. organs from genetically dissimilar donors), but this presented 
clinicians and investigators with a perplexing quandary: how does one control or prevent 
the immune response in graft rejection? It is interesting to note here that an equally 
significant question spurred by Medawar’s observations was, how does the immune 
system know to recognize self from non-self? This eventually led to the discovery of the 
	5 
major histocompatibility complex (MHC) genes, which play a significant role in 
lymphocyte physiology as well as the tissue typing that is used to match transplant 
recipients with appropriate donors.  
One of the first solutions to this predicament would stem from the anti-folate 
research performed by Sidney Farber and his collaborators during the 1940’s. Farber 
understood that the crucial vitamin, folate (B9), stimulated the proliferation of leukemia 
cells in vitro (Miller, 2006). It stood to reason that folate analogues that antagonized 
endogenous folate could potentially be anti-leukemic, which Farber would eventually 
demonstrate through the clinical use of aminopterin (Farber, Diamond, Mercer, Sylvester, 
& Wolff, 1948). By the 1950’s, investigators in other fields were adopting a similar 
practice in rational drug design to discover other potential anti-cancer drugs. In the field 
of purine metabolism, Gertrude Elion and George Hitchings were developing purine 
analogues after early studies showed that these compounds could inhibit the growth of 
bacterial cells (Elion, 1989). This ultimately led to the chemical synthesis of 6-
mercaptopurine (6-MP) (Elion, Hitchings, & Vanderwerff, 1951) and subsequently, 
azathioprine, an immunosuppressant anti-proliferative agent used today under certain 
circumstances of transplant care (Schumacher & Gajarski, 2011). The discovery of 
azathioprine was the result of alterations to 6-MP, which at the time showed promise as 
an anti-leukemic and immunosuppressant drug—azathioprine is the prodrug of 6-MP and 
is converted to 6-MP in the bloodstream by erythrocyte glutathione (De Miranda, 
Beacham, Creagh, & Elion, 1973; Elion, 1989). Subsequent comparison studies of the 
two drugs demonstrated azathioprine to be less toxic than 6-MP (Elion, Bieber, & 
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Hitchings, 1960) and better at suppressing the immune response to allogeneic renal grafts 
in canine transplant models (Calne, 1961). As a result, azathioprine was tested in the 
clinic in combination with the corticosteroid, prednisone, which allowed transplantation 
between genetically unrelated humans for the first time in 1962—one patient out of 8 
treated with azathioprine survived past 6 months (Murray, Merrill, Harrison, Wilson, & 
Dammin, 1963).  
Following the clinical implementation of azathioprine, newer and more potent 
immunosuppressant drugs were being discovered in various bacterial and fungal sources, 
and they remain in use as the standard of care in a majority of today’s transplant 
treatment protocols (Schumacher & Gajarski, 2011). Importantly, the discovery of these 
so-called, “modern immunosuppressants,” coincided with immense leaps in our 
understanding of lymphocyte physiology and the myriad biochemical signaling pathways 
that regulate cellular activity.  
The first modern immunosuppressant to be developed was the calcineurin 
inhibitor (CNI), cyclosporine—discovered in the fungi Cylindrocarpon lucidum and 
Trichoderma polysporum (Dreyfus et al., 1976; Ruegger et al., 1976). Studies done by 
Jean Borel and colleagues during the 1970’s characterized the immunosuppressive 
properties of cyclosporine in various animal models (Borel, 1976; Borel, Feurer, Gubler 
& Stahelin, 1976; Borel, Feurer, Magnee & Stahelin, 1977). In contrast to its anti-
proliferative predecessors, azathioprine and cyclophosphamide, cyclosporine 
demonstrated a unique ability to specifically and reversibly suppress both cell-mediated 
and humoral immunity without compromising bone marrow function (Starzl, 2000). 
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Further testing in models of allogeneic heart, kidney, liver, and pancreas transplantation 
revealed that cyclosporine had a significant effect in delaying graft rejection (Calne & 
White, 1977; Calne et al., 1979; Calne, White, Rolles, Smith & Herbertson, 1978; Green 
& Allison, 1978; Kostakis, White & Calne, 1977). By the 1980’s, cyclosporine had 
become a mainstay in clinical transplant immunosuppression. It improved outcomes for 
renal transplantation (Starzl et al., 1980) and elevated the endeavors in heart, liver, and 
lung transplantation to the level of clinical reality (Cooper, 1990; Griffith, Hardesty, 
Deeb, Starzl, & Bahnson, 1982; Reitz et al., 1982; Starzl, Klintmalm, Porter, Iwatsuki, & 
Schröter, 1981).  
 Cyclosporine remained the top-of-the-line immunosuppressant for transplantation 
until 1989, when it was discovered that certain liver transplants could not be protected 
from rejection by cyclosporine alone, but rather by a new kind of CNI, tacrolimus or FK 
506 (Starzl et al., 1989). Unlike cyclosporine, tacrolimus was discovered in a bacterial 
source, Streptomyces tsukubaensis (Kino et al., 1987). The clinical investigation of 
tacrolimus found that it was particularly useful in cases of intractable organ rejection, 
where cyclosporine and other immunosuppressants failed to work. In initial clinical liver 
transplant studies, it was found that approximately 75% of intractably rejecting livers 
could be saved using tacrolimus (Fung et al., 1990). Subsequent clinical trials revealed 
that a similar percentage of intractably rejecting organs could be rescued in kidney and 
thoracic organ transplantation (Armitage, Fricker, Del Nido, Cipriani, & Starzl, 1991; 
Starzl et al., 1989, 1990).  
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Other effective immunosuppressants would also come to be discovered in the 
same time frame as the development of cyclosporine and tacrolimus. The most prominent 
of these drugs are the mechanistic target of rapamycin (mTOR) inhibitors, everolimus 
and sirolimus (rapamycin) (Calne et al., 1989; Schuurman et al., 1997; Thomson & Woo, 
1989). Additionally, an older drug, the antibiotic mycophenolic acid (MPA)—a de novo 
guanine nucleotide synthesis inhibitor—was repurposed as an anti-proliferative 
immunosuppressant (Allison & Eugui, 1993). The immunosuppressant drugs discussed 
up to this point represent the bulwark of modern day immunosuppression: anti-
proliferatives (azathioprine and MPA), CNI’s (cyclosporine and tacrolimus), mTOR 
inhibitors (everolimus and sirolimus), and corticosteroids (prednisone) (Schumacher & 
Gajarski, 2011). The combination use of these immunosuppressants are responsible for 
the remarkable increase in short-term survival of transplant recipients—extending 
survival once measured in days, weeks, and months during the early years of 
transplantation to survival measured in years (1-, 3-, 5-, 10-year time frames and for the 
lucky few, several decades).  
Though transplant recipients have enjoyed a remarkable increase in short-term 
survival since the start of clinical organ transplantation, long-term survival has seen little 
to no improvement in recent decades and remains one of transplantations enduring 
challenges. This challenge stems from the difficulties associated with immunosuppressant 
administration. A crucial aspect of transplant care is the ability of clinicians to mitigate 
the potential adverse effects associated with transplantation. This requires dosing with 
just enough immunosuppressant to prevent acute or chronic graft rejection, while 
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simultaneously aiming to minimize drug-specific toxicities and the long-term risks of 
chronically depressing the immune system. However, many of these problems are 
difficult to avoid despite employing the safest drug regimens.  
In the earliest clinical studies with immunosuppressants, particularly the CNI’s, 
severe toxicities were reported, which included cosmetic changes (e.g. facial 
brutalization, gingival hyperplasia, and hirsuitism), hypertension, metabolic 
derangements (e.g. diabetogenesis and hyperlipidemia), nephrotoxicity, neurotoxicity, 
and pneumonitis (Starzl, 2000; Watson & Dark, 2012). Despite the trial and error 
processes used to determine the dose ceilings and floors for each of the 
immunosuppressants, transplant patients today still suffer from some of these toxicities 
(Starzl, 2000). Additionally, cardiovascular mortality in relation to long-term 
immunosuppression is the leading cause of death amongst transplant patients (Jacques 
Dantal & Soulillou, 2005). Other complications related to long-term immunosuppression 
may arise as well. For instance, patients are at an increased risk of acquiring bacterial and 
fungal infections as well as developing malignancies (Dantal et al., 1998; Dantal & 
Soulillou, 2005; Dharnidharka, Stablein, & Harmon, 2004). Coupled with the high cost of 
immunosuppressant medications, these side effects can lead to patient non-compliance 
with the drug protocol, which is the primary cause of organ failure—due to immune 
rejection—in transplant recipients (Orlando, Soker, Stratta, & Atala, 2013). These 
patients eventually become re-listed for organ transplantation, thus further burdening an 
already strained organ donation system.   
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While immunosuppressants have largely helped to legitimize organ 
transplantation as a practical means of treating end-stage organ failure, it is clear that 
improvements in long-term survival and elimination of immunosuppressant-mediated 
complications and toxicities are a requirement for transplantation to progress beyond its 
current state. For this reason, transplant immunologists have been pursuing an 
understanding of the mechanisms that underlie immune tolerance. By being able to 
induce the acceptance of an organ graft, clinicians may avoid the use of 
immunosuppressant medications that limit long-term survival. The source of inspiration 
for much of the knowledge regarding immune tolerance in organ transplantation would 
come from an unlikely source, English pigs. 
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Immune Tolerance: The Golden Goal of Transplantation 
 The concept of immune tolerance was born of the endeavor to understand an 
enigma that had long-plagued cattle farmers since ancient times, the freemartin cattle. A 
freemartin is the reproductively sterile female that manifests in a majority of heterosexual 
dizygotic twinning events, i.e. male-female fraternal twinning. The mechanism by which 
this occurred was poorly understood and much less was known about how to distinguish 
whether the female twin was developmentally normal or a freemartin. However, by 1916, 
Frank Lillie had demonstrated evidence of fused vascular beds that existed in utero 
between the placenta of the male (bull) twin and that of the female freemartin twin—in 
the birth of a normal bull and normal female, the placental circulation was shown to be 
separate (Lillie, 1916). Thus, freemartinism could be explained by the vascular exchange 
of male-determining “hormonic” factors, which suppress the normal development of the 
female twin’s reproductive system. The implications of shared placental vasculature 
between bull and freemartin twins would have a significant impact on the establishment 
of the concept of immune tolerance.  
 During the early 1940’s, Ray Owen was investigating cattle in a quasi-
commercial context. At the time, American purebred cattle associations in partnership 
with the lab Owen worked for routinely submitted cattle blood samples in order to 
identify purebred individuals (Martin, 2015). To Owen’s surprise, blood tested from a 
bull and freemartin twin pair—they were calves at this point—revealed identical blood 
group characteristics. In cattle breeding, fraternal twinning often resulted from female 
insemination by two different bull fathers. It was therefore reasoned that each fraternal 
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twin, the bull and freemartin, should express different and separate blood group antigens 
corresponding to those that they inherited from their respective bull fathers. The identity 
in blood characteristics that Owen observed between these twin calves upended this logic 
and suggested something of deeper consequence. Subsequent to his initial observations, 
Owen devised a technique by which he could separate erythrocytes by blood group 
antigen (Martin, 2015). In testing hundreds of other bull-freemartin twin pairs, Owen 
revealed that in each case, both twins always shared the same two-erythrocyte 
populations, one population originating from self and the other from the twin. Owing to 
Lillie’s 1916 insight regarding shared in utero vasculature between bull-freemartin twins, 
Owen reasoned that erythrocyte progenitors (described by Owen as “ancestral cells”) 
from each twin must be exchanged during embryonic development so that each twin 
could produce a mixed population of erythrocytes that continues into adulthood (Owen, 
1945). The persistence of a foreign erythrocyte population in each twin and the absence 
of an immunological response to those foreign cells, thus beckoned a new avenue of 
understanding in immunology: that the concept of biological “self” is learned by the 
developing embryo’s immune system. As a consequence, an individual could be made 
immunologically tolerant to any foreign tissue so long as exposure occurs during 
embryological development, but this would remain to be explained conceptually and 
demonstrated experimentally at a later time.  
 Owen’s observations remained dormant until Frank Burnet and Frank Fenner 
conceptualized their “self-marker” hypothesis in their monograph, “The Production of 
Antibodies” (Burnet & Fenner, 1949). Burnet and Fenner attempted to explain how the 
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body’s immune cells could distinguish self from non-self through the employment of 
unique molecular tags—what we now know of as MHC molecules. Armed with the 
observations made by Owen just four years earlier, they also deduced that the antibody 
producing cells of the body could develop a “tolerance” to foreign tissues during 
embryonic life. Burnet and Fenner’s derivation of tolerance from Owen’s observations 
inspired Peter Medawar—who previously investigated the immune nature of graft 
rejection—Rupert Billingham, and Leslie Brent to perform cell transfer experiments in 
mouse embryos (Billingham, Brent, & Medawar, 1953). Suspensions of cells from an 
adult mouse donor were injected into several mouse embryos of a different genetic 
constitution, an allogeneic transplant of sorts. Once those embryos developed into young 
mice, the trio transferred skin grafts from the same adult donor to each young mouse. The 
skin grafts remained intact without showing any evidence of rejection. Additionally, skin 
grafts from a third-party donor were transplanted onto these mice, but these grafts 
eventually demonstrated the characteristic features of rejection. This indicated that the 
tolerance acquired by these mice was specific to the original donor. This “actively 
acquired tolerance” to foreign tissues during embryonic development inspired individuals 
in the transplant field, particularly Roy Calne. In the words of Calne, “[actively acquired 
tolerance] raised an important question not yet answered: could an adult immune system 
be temporarily returned to the fetal state while the organ graft was inserted, and could the 
immune system then regain its protective role, having accepted the foreign graft?” 
(Calne, 2012). 
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While immunologists worked further to understand the mechanisms of tolerance, 
the transplant field pushed onward finding other means of manipulating the immune 
system to make transplantation possible, e.g. testing immunosuppressant drugs. The next 
significant revelation in immune tolerance would not be uncovered until the technical 
challenges of liver transplantation were overcome by the experimental and clinical work 
of Thomas Starzl (Calne, 2012). Owing to the large size of the liver and the considerable 
coagulopathies that are often associated with liver disease, the first clinical liver 
transplantation attempts made by Starzl in 1963 were so unsuccessful that there was an 
agreed moratorium on clinical liver transplantation until further experimental work could 
be done (Calne, 2012; Starzl et al., 1964). However, by 1967, the outcomes of liver 
transplantation were beginning to improve, and thereafter, liver transplantation could be 
done practically in both the experimental and clinical settings.   
This set the stage for Calne to begin his own experimentation with liver 
transplantation, an interest based off of earlier observations that liver allografts in pigs 
experienced mild and prolonged rejection in the absence of immunosuppression—other 
solid organs experienced acute rejection (Calne et al., 1967). In 1969, Calne and 
colleagues found that 12 out of 55 liver transplants in pigs resulted in long-term, 
immunosuppression-free survival (Calne et al., 1969). These liver allografts displayed 
early characteristics of rejection that spontaneously resolved on their own, evidence of 
active immune suppression by the liver. Additionally, these allografts were able to induce 
tolerance to skin and kidney transplants from the same donor, a clear demonstration of 
specific and actively acquired tolerance, but in this case, without the need to revert to an 
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embryonic state as previously postulated by Calne. The results of the 1969 study were so 
astonishing to transplant investigators that it even prompted the publication of an article 
in the Lancet tilted, “Strange English Pigs” (“Strange English Pigs,” 1969), and so it was 
that the liver tolerance effect was established.  
The induction of tolerance in liver allografts was subsequently shown to be 
possible in other species, including mice and rats (Kamada, Brons, & Davies, 1980; Qian 
et al., 1994; Zimmermann, Davies, Knoll, Gokel, & Schmidt, 1984). Starzl also reported 
evidence of liver transplant tolerance in humans during the early 1990’s (Reyes et al., 
1993). Eleven patients displayed stable liver function with no evidence of rejection after 
being taken off of immunosuppressant medications due to non-compliance or 
lymphoproliferative disorder. Since then, the clinical transplantation of the liver has 
clearly recorded lower rates of rejection compared to other transplantable organs, with as 
much as 20% of all liver transplant patients living immunosuppression free (Bishop, 
Bertolino, Bowen, & McCaughan, 2012; Lerut & Sanchez-Fueyo, 2006). Additionally, 
multiple simultaneous-transplant studies in which the liver is transplanted along with 
another solid organ (e.g. the intestines, kidneys, or lungs) have shown that the liver can 
protect these organs from rejection as well—just as was preliminarily shown in Calne’s 
1969 study (Abu-Elmagd et al., 2009; Benseler et al., 2007; Creput et al., 2003; Opelz, 
Margreiter, & Döhler, 2002; Rasmussen, Davies, Jamieson, Evans, & Calne, 1995).  
 The questions that remain are how does the liver establish tolerance for itself and 
other organs? From where does it derive its immunomodulatory properties? The liver’s 
intrinsic immunomodulatory properties are derived from its parenchymal cell (PC) and 
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non-parenchymal cell (NPC) populations. The remainder of this thesis will focus on the 
contributions that certain NPC populations make to the establishment of local and 
systemic immune tolerance in general and in the context of liver transplantation. The 
thesis will then conclude with a discussion of a recent theory of liver transplant tolerance 
induction based on these NPC populations.  
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SPECIFIC AIMS 
 
The objectives of this thesis include the following:  
1. Introduce the liver in a seldom-considered context, its immune function.   
2. Highlight the evidence gathered on specific NPC populations in the liver, which 
contribute to the liver’s ability to skew the immune response in favor of 
tolerance.  
3. Discuss the recent mechanistic hypothesis explaining liver transplant acceptance, 
known as mesenchyme-mediated immune control, and how this new perspective 
of organ-resident mesenchyme cells may affect the future of transplant care.  
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THE LIVER AS A LYMPHOID ORGAN 
 
 As the of the largest solid-organ in the abdominal cavity, the liver is 
unsurprisingly responsible for numerous vital physiological functions, which include 
synthesizing and clearing a multitude of plasma proteins, producing fat-emulsifying bile 
for digestion, regulating glucose storage, and detoxifying and excreting harmful 
compounds of both endogenous and exogenous origin (e.g. metabolic neo-adducts/neo-
antigens and pharmaceutical drugs). What has become clear over the last 50 years, since 
Calne’s discovery of the liver tolerance effect, is that the liver posses additional 
functional roles, bona fide immunomodulatory properties that are as vital to normal 
physiological function as the rest of the liver’s well-characterized roles. These 
immunomodulatory properties are made possible, in part, due to the liver’s location, 
architecture, and PC/NPC populations (Crispe, 2009).  
 The liver is positioned at a unique vascular confluence where it receives large 
volumes blood from systemic circulation, approximately 20% of the cardiac output. The 
nutrient-rich blood of the portal vein mixes with the oxygen-rich blood of the hepatic 
artery upon entering the liver. This nutrient rich blood, low in oxygen tension, then 
sluggishly percolates through the maze-like microvasculature of the liver known as the 
hepatic sinusoids. The sheer volume of the liver and its numerous parallel sinusoidal 
vessels, coupled with occasional microvascular occlusions by intraluminal Kupffer cells 
(KC, the resident liver macrophage), account for the low perfusion pressure and the slow 
flow of blood that is characteristic of the liver—in some cases, the flow of blood can 
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even be completely stopped or reversed due to the presence of occluding KCs (MacPhee, 
Schmidt, & Groom, 1995). This hemodynamic characteristic of the liver is what allows 
its PC and NPC populations to effectively act as immune regulators. The slow flow of 
blood gives scavenging cells ample time to not only clear the blood of gut-derived 
nutrients, but also of innocuous food antigens, bacterial metabolites, bacterial cell 
components (e.g. lipopolysaccharide (LPS), flagellin, peptidoglycans, etc.), and other 
debris, self or non-self, originating from the gut (Horst, Neumann, Diehl, & Tiegs, 2016; 
Thomson & Knolle, 2010). In a non-hepatic context, challenge by an antigenic load 
similar to that found in the portal vein would normally result in a powerful inflammatory 
immune response. Despite a large influx of antigens coming from the portal vein and the 
persistent stimulation of innate immune receptors on both PC and NPC populations, the 
liver responds by active immune suppression and the production of soluble immune-
regulatory cytokines like interleukin-10 (IL-10), transforming growth β (TGFβ), and 
prostanoids (prostaglandin E2 (PGE2)), thus favoring a state of tolerance as opposed to a 
state of immunity (Crispe, 2009; Gao, Jeong, & Tian, 2008; Knolle & Gerken, 2000). 
These mechanisms presumably evolved to prevent the liver, the source of so many vital 
physiological functions, from inflicting immune-mediated damage to itself, as can be 
seen in cases of autoimmune hepatitis (Crispe, 2009).  
 In contrast to other immune privileged organs like the eye, which rely on 
compartmentalization to avoid the immune system (Niederkorn, 2013), the liver is unique 
in that it uses its PC and NPC populations to actively suppress immune responses in order 
to achieve immune tolerance (Horst et al., 2016; Wohlleber & Knolle, 2016). These cells 
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are far more than just simple scavengers. They act via antigen-dependent and 
independent mechanisms to skew the immune response towards tolerance. As is the case 
with antigen clearance, the slow flow of blood provides PCs and NPCs with ample time 
to make extensive interactions with passing leukocytes, T cells in particular. While 
multiple cell populations of the liver contribute to immune tolerance in varying contexts, 
the next couple of subsections of will be dedicated to describing the general immune 
suppressive capabilities of two NPC populations of mesenchymal origin that have drawn 
significant interest for their function in the induction of liver transplant tolerance, the 
liver sinusoidal endothelial cells (LSEC) and hepatic stellate cells (HSC).  
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Liver Sinusoidal Endothelial Cells 
 The LSEC is the most prominent NPC population in the liver, comprising 
upwards of 50% of all NPCs (Demetris et al., 2016). They are positioned at the interface 
between the sinusoid lumen and the subendothelial space of Dissé, regulating the two-
way exchange of materials by altering the pore size of their fenestrations. Due to the lack 
of proteinaceous diaphragms that span individual fenestrations and a proper basement 
membrane beneath the LSECs, the fenestrations can accommodate the passage of entire 
cells or cellular processes, which is critical to the interaction of passing leukocytes with 
subendothelial HSCs and hepatocytes (Demetris et al., 2016). Beyond acting as a semi-
permeable barrier between the blood and liver parenchyma, LSECs are also efficient 
scavenging and antigen-presenting cells (APC) (Ebrahimkhani, Mohar, & Crispe, 2011; 
Limmer et al., 2000; Schurich et al., 2009) 
  Due to the remarkably efficient scavenging capability of LSECs, they compete 
with liver dendritic cells (DC) for exogenous antigen that can be processed and presented 
on MHC class II (MHC-II) molecules, which are recognized by passing naïve and 
effector CD4+ T helper (Th) cells (Limmer et al., 2000; Schurich et al., 2009). Under 
steady-state conditions, LSECs express only low levels of MHC-II and T-cell co-
stimulatory ligands, CD80/86 (see “2-Signal Model” in Appendix I) (Knolle et al., 
1998). The LSEC expression of MHC-II and CD80/86 are kept low by 
immunosuppressive IL-10, which is expressed by various liver cells in response to the 
physiological levels of LPS arriving from the gut. Despite the low levels of MHC-II and 
CD80/86, LSECs are still able to activate both naïve and effector Th cells (Carambia et 
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al., 2013, 2014; Kruse et al., 2009). However, the outcomes of LSEC-mediated activation 
diverge with normal Th-cell activation due to the LSEC’s lack of co-stimulatory ligand 
expression and the necessary T cell-activating cytokine, IL-12.  
 In the context of naïve Th-cell activation, LSECs have been shown induce a Th-
cell phenotype that resembles regulatory T cells (Treg) in function, but lacks the classical 
Treg markers CD25 and Foxp3 (Kruse et al., 2009). These non-conventional 
CD25lowFoxp3– Tregs were shown to express the immunosuppressive cytokines, IL-4 and 
IL-10, resulting in the suppression of T-cell proliferation and function in vitro and the 
suppression of autoimmunity in a murine model of autoimmune hepatitis (Kruse et al., 
2009). LSECs may also induce the production of conventional Tregs (CD25highFoxp3+), 
but in a TGFβ-contact-dependent manner (Carambia et al., 2014). These LSEC-induced 
conventional Tregs effectively suppress T-cell immunity and induce systemic tolerance, 
as evidenced by a murine model of experimental autoimmune encephalomyelitis 
(Carambia et al., 2015). In this model, auto-antigen (i.e. the antigen causing 
autoimmunity) was delivered specifically to LSECs via nano-particles. The LSECs 
subsequently induced the differentiation of auto-antigen-specific conventional Tregs that 
suppressed the autoimmune condition, generating systemic tolerance to the auto-antigen.  
In the context of effector Th-cell activation, LSECs are able to modulate the 
functions of these Th cells so as to induce tolerance. Th1 and Th17 effector cells 
normally differentiate in response to intracellular and extracellular pathogens, 
respectively, and they secrete the inflammatory cytokines interferon-γ (IFN-γ) and IL-17 
to aid in pathogen elimination (Parham, 2014). When Th1 and Th17 cells were co-
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cultured with LSECs, their secretion of inflammatory cytokines was inhibited (Carambia 
et al., 2013). This inhibition is accomplished by LSEC secretion of immunosuppressive 
IL-10, as well as the increased expression of the co-inhibitory ligand, programmed death-
ligand 1 (PD-L1) (see “2-Signal Model” in Appendix I). Additionally, Th1 cells have 
been found to secrete their own IL-10 in response to Notch receptor engagement by 
Notch ligands expressed on LSECs (Neumann et al., 2015). LSECs may also modulate 
the function of Th2 effector cells. Th2 cells normally differentiate in response to 
extracellular parasitic infection and secrete anti-inflammatory cytokines that initiate 
repair and recovery of the tissues that have been damaged by the parasite (Parham, 2014). 
It has been shown that LSEC activation of Th2 cells leads to their proliferation, resulting 
in increased levels of anti-inflammatory cytokine IL-4, thus contributing further to 
tolerance (Klugewitz et al., 2002).  
 LSECs are also capable of activating naïve CD8+ cytotoxic T lymphocytes (CTL) 
through the expression of MHC class I (MHC-I) molecules. Similar to liver DCs, LSECs 
harbor cross-presentation mechanisms (see “Cross-Presentation” in Appendix II) 
(Ebrahimkhani et al., 2011; Limmer et al., 2000; Schurich et al., 2009), which allow 
exogenously derived antigens that are normally presented by MHC-II molecules to be 
diverted towards presentation on MHC-I molecules—MHC-I is recognized exclusively 
by CTLs. This allows LSECs to use antigens of exogenous origin to trap and modulate 
the function of naïve CTLs specific for these antigens. Upon cognate interaction between 
LSEC MHC-I and naïve CTL T-cell receptor (TCR), naïve CTLs become non-responsive 
or anergic (Limmer et al., 2000) and transform into long-lived, memory-like T cells that 
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express high levels of the anti-apoptotic protein, bcl-2 (von Oppen et al., 2009). The 
continued suppression of LSEC-activated CTLs is dependent on the upregulation of the 
co-inhibitory signaling via PD-L1/PD-1, which occurs after initial cognate interactions 
between the LSEC and naïve CTL. It is a similar suppressive mechanism to that seen in 
LSEC modulation of the Th1 and Th17 effector cells. This “tolerized” state of the CTL, 
however, is reversible upon sufficient stimulation of CD28 co-stimulatory receptor on the 
anergic CTL (Diehl et al., 2008). The induction of this non-responsive state is 
presumably to save pathogen-specific naïve CTLs from clonal deletion mediated by DCs 
under non-inflammatory conditions. In non-inflammatory conditions, DCs do not express 
the necessary co-stimulatory ligands to fully activate naïve CTLs, thus resulting in their 
elimination by induced apoptosis (Horst et al., 2016). The anergic phenotype of LSEC-
activated CTLs is thus beneficial in the context of inducing systemic tolerance to organ 
transplants and saving unique T-cell clones that are pathogen-specific from clonal 
deletion. However, it is interesting to note that this mechanism may be harmful in the 
context of immunity to cancer, since cancer-specific CTLs maybe tolerized and prevented 
from enacting necessary cytolytic functions on cancer cells.  
 A remaining aspect of LSEC-mediated immune suppression to consider is 
antigen-independent (non-APC) function as an immune “bystander” (Horst et al., 2016; 
Schildberg, Sharpe, & Turley, 2015). As has been discussed up to this point, LSECs are 
particularly efficient at directly modulating the immune responses of Th cells and CTLs 
by interacting with these cells in an antigen-dependent context. However, LSECs express 
a unique adhesion molecule known as liver sinusoidal endothelial cell lectin (LSECtin), 
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which binds to intercellular adhesion molecule 3 (ICAM-3) on activated T cells (Liu et 
al., 2004). The ability to non-specifically adhere to activated T cells is what allows the 
liver to sequester large amounts of these cells and suppress their function. It has been 
shown in a murine model of T cell-mediated acute hepatitis, that the absence of LSECtin 
can exacerbate the disease, while exogenous addition of recombinant LSECtin can lead to 
partial recovery (Tang et al., 2009). In addition to non-specific trapping of activated T 
cells, LSECs are capable of preventing DCs from activating naïve CTLs, thus abrogating 
DC-mediated T-cell immunity (Schildberg et al., 2008). This “vetoing” capacity of 
LSECs is achieved through contact-dependent mechanisms, which downregulate the 
expression of DC co-stimulatory ligands and the T cell-activating cytokine, IL-12. The 
permanence of this mode of T-cell suppression was highlighted by the fact that 
supplementation of exogenous stimulatory signals could not rescue these cells from 
suppression. This contact-dependency in vetoing APC function has also been observed in 
HSCs, suggesting that this is a broad mechanism employed by liver NPCs to alter the 
immune function of certain APCs (Horst et al., 2016; Schildberg, Wojtalla, et al., 2011).  
LSECs are efficient immunosuppressive cells that operate through antigen-
dependent and independent mechanisms. The culmination of these mechanisms allows 
LSECs to effectively induce immune tolerance rather than immunity, thus providing a 
partial picture of how tolerance may be induced in liver transplantation and co-
transplantation, among other contexts.  
 
 
	26 
Hepatic Stellate Cells  
The HSC is the second largest stromal cell population in the liver after LSECs and 
comprises 10-15% of the total liver cell population (Demetris et al., 2016). They function 
as liver-specific pericytes that occupy the subendothelial space of Dissé, between the 
fenestrated LSECs and plates of hepatocytes. Under steady state non-inflammatory 
conditions in the liver, HSCs have numerous quiescent functions of which the most 
prominent are vitamin A storage, the deposition and turnover of extracellular matrix 
(ECM) in the space of Dissé, and the control of microvascular blood flow by regulation 
of sinusoidal vascular tone (Hellerbrand, 2013). However, during states of inflammation 
or liver damage, HSCs become activated and assume new functions. They may trans-
differentiate into contractile myofibroblasts, which are responsible for the collagen and 
ECM deposition seen in liver fibrosis. Additionally, activated HSCs may assume various 
immunomodulatory functions.  
Activated HSCs have been reported to interact with CD4+ Th cells in a possible 
antigen-presenting context. In a murine hepatic fibrosis model, activated HSCs were 
found to be in close proximity to Th cells in periportal regions, suggesting that the HSCs 
may be modulating T-cell activity by antigen presentation (Muhanna, Horani, Doron, & 
Safadi, 2007). These purely qualitative in vivo observations, however, have been 
challenged by in vitro studies, which cast doubt on the antigen-presenting capacity of 
activated HSCs. These studies have demonstrated that purified HSCs express low levels 
of MHC-II molecules and lack co-stimulatory ligand expression (Ichikawa, Mucida, 
Tyznik, Kronenberg, & Cheroutre, 2011). Additionally, they exhibit poor antigen uptake 
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abilities in comparison with LSECs and DCs (Schildberg, Kurts, & Knolle, 2011). 
However, the APC function of activated HSCs may be context dependent, as the addition 
of exogenous IFN-γ to HSC culture increased the expression of molecules required for 
antigen processing and presenting (Ichikawa et al., 2011). Ascertaining the precise degree 
to which HSCs function as APCs has been difficult, especially since obtaining highly 
pure HSC populations for in vitro culture and replicating the exact in vivo conditions of 
the liver remain technically challenging. Further studies will be required to clarify 
weather HSCs are sufficiently competent to be considered as an APC population in the 
liver.  
In terms of antigen-presentation to CD8+ CTLs, it has been found that HSCs lack 
the ability to cross-present antigens as do LSECs and DCs (Ichikawa et al., 2011). While 
this result may suggest an inability of HSCs to activate CTLs using exogenously derived 
antigens on MHC-I, HSCs may still be able to acquire this APC function since it has been 
shown that HSCs engage in a process known as trogocytosis (Ichikawa et al., 2011). 
During trogocytosis, certain cell populations are able to exchange pieces of cell 
membrane that contain MHC molecules as well as co-stimulatory or co-inhibitory ligands 
(Huang et al., 1999). By this mechanism, it is possible for HSCs to acquire the needed 
cell surface molecules to participate in antigen-presentation and subsequent activation of 
both Th cells and CTLs, however, further study is required to understand the extent to 
which this happens.  
 Though the immunomodulatory function of HSCs as APCs has been largely 
questioned, their functional role as immunosuppressive bystander cells acting in an 
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antigen-independent (non-APC) manner is well characterized. Upon activation in liver 
inflammation or injury, HSCs acquire robust T-cell suppressive capabilities in addition to 
their pro-fibrotic capacity. The ability to inhibit T cells is brought about by increased 
expression of co-inhibitory ligand PD-L1 and immunosuppressive cytokines IL-6, IL-10, 
and TGFβ, after exposure to inflammatory cytokine IFN-γ—shown to be dose dependent 
(Charles et al., 2013). Co-culture of activated HSCs with activated T cells demonstrated 
HSC-dependent initiation of T-cell apoptosis, presumably by contact-dependent ligation 
of HSC PD-L1 with T-cell PD-1. Other studies have shown that HSC PD-L1 does not act 
alone and that increased expression of B7-homolog 4 (B7-H4, another co-inhibitory 
ligand related to PD-L1) and tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL) also resulted in T-cell suppression and apoptosis (Chinnadurai & Grakoui, 
2010; Yang et al., 2010). HSCs have also been observed to indirectly suppress T-cell 
function by induction of Treg differentiation from naïve Th cells in an antigen-
independent manner. When HSCs were co-cultured with naïve Th cells in the presence of 
liver DCs (the stand-in APCs), HSC-derived all-trans retinoic acid (ATRA) and TGFβ 
were able to bias naïve Th cell differentiation towards conventional CD25highFoxp3+ 
Tregs (Dunham et al., 2013). Additional studies are needed to identify the mechanism by 
which HSC-derived ATRA induces Treg differentiation.    
 In addition to directly suppressing T-cell function and inducing Treg 
differentiation, HSCs have also been observed to induce other immunosuppressive cell 
populations. Activated HSCs are able to interact with peripheral blood monocytes in the 
sinusoid lumen via long cytoplasmic extensions that traverse LSEC fenestrations 
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(Demetris et al., 2016; Höchst et al., 2013). These peripheral blood monocytes are 
induced by HSCs to differentiate into myeloid-derived suppressor cells (MDSC), which 
effectively inhibit T-cell proliferation and function. Other bystander functions of HSCs 
include a similar APC vetoing capacity as seen in LSECs. Through contact-dependent 
mechanisms and expression of ATRA and IL-10, HSCs can depress the APC function of 
liver DCs, thus preventing DC-mediated T-cell activation (Bhatt et al., 2014; Lee et al., 
2005).  
HSCs are potent immunosuppressive cells that most likely act primarily in an 
antigen-independent fashion. Through robust contact-dependent T-cell suppression, 
induction of suppressor cell populations like MDSCs and conventional Tregs, and 
modulating DC APC function, these cells can work collectively with LSECs to induce 
formidable local and systemic immune tolerance that allow for the induction of liver 
transplant tolerance.  
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IFN-γ SIGNALING AND MESENCHYME-DERIVED NPCs MEDIATE 
TOLERANCE INDUCTION IN LIVER TRANSPLANTATION 
 
 In 2003, Philip Halloran’s group demonstrated that IFN-γ signaling is absolutely 
required for spontaneous liver transplant acceptance (Mele et al., 2003). Wild type (WT) 
liver allografts were transplanted into mice of WT and IFN-γ knockout (KO) 
backgrounds. It was found that allografts in IFN-γ KO mice succumbed to acute rejection 
with none of the grafts surviving beyond 14 days. On the other hand, grafts in WT 
recipients demonstrated long-term survival with nearly half of the allografts surviving 
past 100 days. These results were somewhat counterintuitive, as IFN-γ was understood to 
be an inflammatory cytokine expressed by various effector T (Teff) cell populations that 
mediate graft rejection. This raised several important questions: Why is IFN-γ required 
for spontaneous graft acceptance? What cellular populations does IFN-γ act through? 
What are the downstream mediators of IFN-γ signaling that bring about acceptance? Etc.  
These results are striking to say the least, however, it would take another 12 years 
before the questions raised by this study would begin to get answered in full. During the 
early 2000’s, the individual roles of different liver cell populations in tolerance induction 
were still being parsed out, which may in part explain the delayed investigation into IFN-
γ signaling in the context of transplantation. In 2015, Shiguang Qian’s group determined 
that two mesenchyme-derived cell populations, the LSECs and HSCs, are instrumental in 
inducing spontaneous liver allograft acceptance via IFN-γ signaling (Morita et al., 2015). 
The following sub-section is a brief summary of key results from that study.  
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Rejection is Necessary to Induce Spontaneous Liver Allograft Acceptance 
 In the study performed by Morita et al., donor liver allografts were derived from 
both WT and IFN-γ receptor (IFN-γR) KO mice. Both types of allografts were 
transplanted into WT recipients of a different MHC constitution (Figure 2) in order to 
recapitulate and corroborate the findings of Mele et al. All WT allografts demonstrated 
long-term survival (>80 days), while none of the IFN-γR KO allografts survived past 15 
days, thus confirming that IFN-γ signaling is indispensible to spontaneous liver allograft 
acceptance.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. A schema of the initial transplant experiments used to corroborate the 
finding that IFN-γ signaling is indispensible to spontaneous liver allograft 
acceptance. Donor liver allografts originated from mice of two different backgrounds, 
WT C57BL/6 and IFN-γR KO, but both mice were similar in MHC constitution, H-2b. 
These livers were subsequently transplanted into mice of WT C3H background with a 
different MHC constitution, H-2k. WT C3H mice that received WT allografts 
demonstrated long-term survival (>80 days), while WT C3H mice that received IFN-γR 
KO allografts succumbed to acute rejection, none surviving past 15 days. This confirmed 
that IFN-γ signaling is indispensible for spontaneous allograft acceptance. Figure was 
created by the author (represents methodology in Morita et al., 2015).  
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 Qualitative analysis of WT and IFN-γR KO liver allografts by hematoxylin and 
eosin (H&E) stain and immunohistochemistry (IHC) for CD4 and CD8 T-cell markers 
revealed that IFN-γR KO allografts were characterized by dense lymphocytic infiltrate 
containing an excess of CD8+ T cells in comparison to WT allografts (Figure 3). The WT 
allografts contained only marginal levels of lymphocytic infiltrate and contained lower 
levels of CD8+ T cells. The levels of CD4+ T cells were similar between WT and IFN-γR 
KO allografts suggesting that IFN-γ signaling is somehow involved in the clearance of 
CD8+ T cells. Additionally, long-term follow up of WT allografts revealed that the 
number of CD8+ T cells decreased over time with CD4+ T cells becoming predominant. 
These results were confirmed by quantitative flow analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. IFN-γR KO allografts are characterized by dense lymphocytic infiltrate. 
The two panels on the left are H&E stains demonstrating panacinar lymphocytic 
infiltration of IFN-γR KO allografts and marginal periportal infiltration of WT allografts. 
IHC for CD4 (red) and CD8 (green) in the two right-hand panels shows the excess build 
up of CD8+ T cells in IFN-γR KO allografts, suggesting IFN-γ signaling is required for 
clearance of CD8+ T cells. Figure taken from (Morita et al., 2015).  
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 To determine if the defective clearance of CD8+ T cells in IFN-γR KO allografts 
was in relation to inadequate induction of apoptosis, terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) staining for evidence of apoptotic cells and 
Western blot for the apoptotic protein, procaspase 3, was performed on lymphocytic 
infiltrates from both grafts. It was found that WT allografts contained far higher levels of 
TUNEL+ cells and procaspase 3 in comparison to IFN-γR KO allografts, thus 
demonstrating that intact IFN-γ signaling is required for the induction of T-cell apoptosis. 
To take things one step further, Morita et al., performed adoptive cell transfer of donor-
specific CD8+ Teff cells (T cells specific for donor MHC, H-2b) into WT and IFN-γR KO 
allografts. Flow analysis of subsequent graft-infiltrating T cells for evidence of 
proliferation and apoptosis revealed that WT allografts could effectively clear these 
donor-specific CD8+ Teff cells while IFN-γR KO allografts could not, thus indicating 
that IFN-γ signaling is a requirement for induction of apoptosis in CD8+ Teff cells, 
importantly, donor-specific CD8+ Teff cells.  
 In the next phase of experiments, Morita et al. tested the effect of IFN-γR 
deficiency on the response of different cell populations in order to deduce which cells 
were acting through IFN-γ signaling to bring about allograft acceptance. In examining the 
suppressor cell populations, namely Tregs and MDSCs, it was found that counts of these 
cells were equally elevated in both WT and IFN-γR KO allografts compared to syngeneic 
transplant controls (these controls were liver transplants from one WT C3H mouse to 
another genetically identical WT C3H mouse, which should not elicit an immune 
response). This suggested that suppressor cell populations are mobilized early in the graft 
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rejection response and do not rely on IFN-γ signaling for induction. Since the induction 
of Tregs and MDSCs was unaffected by IFN-γR deficiency, this indicated that these cells 
are not sufficient to induce allograft acceptance—because the end result is still acute 
rejection in IFN-γR KO allografts.  
 Liver NPCs were also considered due to their known protective and tolerogenic 
roles in the liver. NPCs were particularly appealing since it was known that hepatocyte 
cellular transplantation (which lacks NPCs) invariably suffers rejection (Bumgardner et 
al., 1998). This hinted that allograft NPCs were critical for tolerance induction and 
acceptance in whole-liver transplantation. Upon examining NPC populations in the liver, 
Morita et al. discovered that NPCs of hematopoietic origin (CD45+) are rapidly replaced 
by recipient CD45+ NPCs following transplantation. On the other hand, non-
hematopoietic (CD45–) NPCs remain intact, therefore it was reasoned that CD45+ NPCs 
likely do not contribute to establishing tolerance induction and allograft acceptance. In 
one-way mixed leukocyte reaction (MLR) for T-cell proliferation, WT allograft-derived 
CD45– NPCs exhibited effective suppression of the T-cell proliferative response while 
IFN-γR KO allograft-derived CD45– NPCs exhibited near complete loss of their 
inhibitory function. Additional MLR experiments with activated donor-specific CD8+ 
Teff cells demonstrated that IFN-γR KO allograft-derived CD45– NPCs were unable to 
inhibit CD8+ Teff cell proliferation or induce apoptosis, thus signifying that CD45– NPCs 
are reliant on intact IFN-γ signaling to perform these functions.  
 In identifying the downstream mediators of IFN-γ signaling in CD45– NPCs, 
Morita et al. compared the cell surface expression profiles of WT and IFN-γR KO 
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allograft-derived CD45– NPCs. It was noted that B7-H1 expression was reduced on IFN-
γR KO allograft-derived CD45– NPCs—B7-H1 is the co-inhibitory ligand, PD-L1. The 
ligation of PD-L1 on CD45– NPC with co-inhibitory receptor PD-1 on CD8+ Teff cells is 
likely what mediated the induction of Teff-cell apoptosis and the inhibition of the T-cell 
proliferative response. This was confirmed by B7-H1 KO studies. IFN-γ signaling is 
therefore critical to the expression of B7-H1 on allograft-derived CD45– NPCs, which 
mediates the aforementioned effects on T cells.  
 Cell-specific monoclonal antibodies were used to reveal the precise identity of the 
CD45– NPCs. It was found that the expression of B7-H1 tightly correlated with cells that 
were positive for CD105 (LSECs) and desmin (HSCs)—cells of mesenchymal origin 
(Figure 4). To further test the immunomodulatory properties of these cells, isolated 
LSECs and HSCs were co-transplanted (separately) with pancreatic islet allografts into 
type I diabetic mice. Both LSECs and HSCs allowed for prolonged survival of islet 
allografts, though HSCs demonstrated more potent immunosuppressive abilities. 
Additional experiments were conducted to confirm that these cells also possessed 
immunosuppressive capabilities in a human context. Isolated human liver CD45– NPCs 
were found to similarly respond to IFN-γ by upregulating B7-H1 expression in a dose-
dependent manner. Lastly, when co-cultured with activated T cells in one-way MLR, the 
CD45– NPCs were able to inhibit the T-cell proliferative response. 
The results of this study suggest that the pro-inflammatory environment (high 
local concentrations of IFN-γ) of the liver generated by the initiation of a T cell-mediated 
rejection (TCMR) response by the recipient, allows liver graft CD45– NPCs to upregulate 
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the expression of B7-H1 co-inhibitory ligand and thereby suppress the proliferation of 
CD8+ Teff cells and induce their apoptosis. The elimination of donor-specific CD8+ Teff 
cells thus generates a state of specific immune tolerance to the donor liver allograft, thus 
explaining spontaneous allograft acceptance in the liver.  
 
Figure 4. CD45– NPCs are LSECs and HSCs. To reveal the precise identity of allograft 
CD45– NPCs, monoclonal antibodies were used to identify specific cell populations. By 
identifying overlapping expression of cell-surface markers with B7-H1 expression, the 
identities of the CD45– NPCs were revealed to be LSECs and HSCs. In the top row of 
panels, DAPI (nuclear expression), CD105 (LSEC cell-surface marker), and B7-H1 
expression are shown separately and in unison at the far right. A similar display is made 
for desmin-expressing HSCs in the bottom row of panels. Figure taken from (Morita et 
al., 2015).  
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DISCUSSION 
 
The study recently performed by Morita et al. suggests that rejection is a 
necessary precondition to liver transplant acceptance, a counterintuitive conclusion made 
clear by a mechanistic explanation derived from their results. After reperfusion of a liver 
transplant, donor antigen floods the liver-draining lymph nodes and spleen of the 
recipient, where APCs present this antigen to activate donor-specific T cells into Teff 
cells—the beginnings of the graft rejection response. Due to the efficient trapping of Teff 
cells in the liver via LSEC-expressed LSECtin as well as other antigen-dependent and 
independent mechanisms, large amounts of Teff cells begin to accumulate in the liver 
where they secrete the inflammatory cytokine, IFN-γ. The greater the local concentration 
of IFN-γ, the greater the upregulation of B7-H1 co-inhibitory ligand on liver 
mesenchymal NPCs like LSECs and HSCs. The ligand B7-H1 expressed by LSECs and 
HSCs with PD-1 co-inhibitory receptor expressed by Teff cells results in Teff cell 
proliferative inhibition and subsequent apoptosis, thus eliminating large amounts of 
donor-specific Teff cells that would have otherwise continued to cause rejection. The 
recipient has thereby actively acquired specific tolerance to the liver allograft. This 
negative feedback loop between Teff cells and graft mesenchymal cells is the basis for 
the novel hypothesis, mesenchyme-mediated immune control (MMIC), which was 
proposed by Morita et al.  
Though the study conducted Morita et al. considers one aspect of graft 
mesenchyme-mediated immune suppression (i.e. IFN-γ-stimulated Teff cell elimination), 
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the MMIC hypothesis suggests that graft mesenchyme-derived cells use various 
mechanisms that work in concert to effectively suppress the recipient’s donor-specific 
immune response. As was discussed in previous sections, the mesenchyme-derived 
LSECs and HSCs are competent and potent immunosuppressive cells that work through 
differing antigen-dependent and independent mechanisms to accomplish tolerance. 
Surely in the context of inducing liver transplant tolerance, LSEC and HSC-mediated 
induction of Tregs and MDSCs, modulation and suppression of Teff function, and 
expression of immunosuppressive cytokines work in unison with IFN-γ-mediated clonal 
deletion of donor-specific Teff cells to accomplish formidable specific tolerance for liver 
allografts.  
As mesenchyme-derived cells are common to all organs, it is likely that MMIC is 
not a singular characteristic of the liver, but a potential mechanism shared by many 
organs. The liver is not the only organ to have recorded instances of spontaneous 
acceptance. In fact, there have been instances of spontaneous acceptance in experimental 
kidney transplantation, though this occurs at a far lower rate than what is observed in the 
liver (Russell, Chase, Colvin, & Plate, 1978). Regardless, certain organs contain 
homologous cells to that of the LSEC and HSC in the liver. Endothelial cells are ever 
present in all organs and stellate cells/pericytes are seen in other organs as well, e.g. the 
intraglomerular mesangial cell in the kidneys. The vastly differing capabilities of MMIC 
between other organs and the liver may be due to several liver-intrinsic factors. The liver 
is a large solid organ, and by virtue of its mass it contains more mesenchyme-derived 
cells from which to perform MMIC with. Additionally, the liver has a specialized tissue 
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architecture and microenvironment, characterized by slow blood flow and soluble 
immunosuppressive mediators, which likely contribute to the ability to perform MMIC. 
Lastly, the liver contains evolved mechanisms for immune suppression in order to deal 
with the high antigenic load coming from the portal vein that other organs just simply 
lack. In any case, the concept of MMIC as a universal mechanism of tolerance induction 
shared by all organs may be clinically useful. There is potential for co-transplantation of 
purified mesenchyme-derived graft cells or even in situ enhancement of graft 
mesenchyme cells. As it stands, the effort to improve transplantation by using 
mesenchyme-derived cells has already begun in experimental models, notably, by co-
transplanting pancreatic islet allografts with HSCs, Sertoli cells, and mesenchymal stem 
cells (Figliuzzi et al., 2009; Morita et al., 2015; Suarez-Pinzon et al., 2000). 
 There are other significant clinical implications for MMIC as well. In returning to 
the discussion of LSEC and HSC-mediated clonal deletion of donor-specific Teff cells, it 
is exceptional that the precondition to tolerance induction is rejection and inflammation. 
The significance of rejection-mediated tolerance has to do with current clinical practices 
in transplantation. Most transplant centers globally (50-70%) start patients on 
immunosuppression during the peri- and post-operative period (Schumacher & Gajarski, 
2011). By starting patients on immunosuppression, particularly as it pertains to liver 
transplantation, the recipient is prevented from mounting a graft rejection response that is 
required for tolerance induction. By suppressing T-cell activation and proliferation 
through immunosuppression, there cannot be sufficient graft accumulation of Teff cells 
that secrete IFN-γ, thus abrogating the negative feedback loop enforced by graft 
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mesenchyme-derived cells. Though this is purely speculating based off of the preliminary 
experimental results from the study by Morita et al., it will be interesting to see how 
transplant centers might integrate rejection-mediated tolerance, at least with liver 
transplant patients, should this concept gain more traction in the clinic.  
 Inducing liver transplant tolerance in the clinic may be aided by identifying 
predictive biomarkers. A recent review canvassed efforts to identify useful biomarkers, 
which have focused on recipient characteristics of peripheral blood including the ratio of 
monocytoid dendritic cells to plasmacytoid dendritic cells, the relative numbers of Tregs, 
or ratios of other T-cell subsets (Baroja-Mazo et al., 2016). While these characteristics 
may turn up as useful diagnostic tools, it has become clear from MMIC that the effort to 
find useful biomarkers should also include the donor/allograft. It may be possible to 
identify elements of the IFN-γ/B7-H1 pathway that may serve as useful predictors of 
tolerance induction.  
 The induction of immunosuppression-free transplant tolerance, like that seen in 
liver, has been the goal of transplant investigators for decades. MMIC is a unique 
hypothesis that offers a fresh perspective on the possibility of inducing transplant 
tolerance not only in the liver, but also in the other transplantable organs. With a renewed 
focus on graft mesenchyme-derived cells, further studies should continue to investigate 
the liver and its unique cellular populations, while also delving into the potential 
immunomodulatory properties of other organ mesenchyme-derived cells. Additionally, 
clinical applications of MMIC should be evaluated to identify new therapeutic targets and 
strategies for transplant care.  
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APPENDIX I 
2-Signal Model 
 During the activation of a naïve T cell, 2 essential signals are required for full 
activation into an Teff cell (1) engagement of the T-cell receptor (TCR) by its cognate 
peptide:MHC complex [the antigen-specific signal] and (2) engagement of the co-
stimulatory receptor, CD28, by its ligands CD80/86 [the co-stimulatory signal]. Under 
steady state conditions, professional antigen-presenting cells (APC) like dendritic cells 
(DC) do not express co-stimulatory ligand. If a naïve T cell were to engage a DC in the 
absence of co-stimulatory ligand, these cells would be signaled to undergo apoptosis or 
anergy (induction of functional un-responsiveness). However, during an inflammatory or 
infectious state, DCs can acquire co-stimulatory ligand expression. As a result, DCs can 
provide a Signal 1 (so long as that they present the proper peptide:MHC) and a Signal 2 
(now that they express co-stimulatory ligand). APCs can also express co-inhibitory 
ligands like PD-L1 (B7-H1) that interact with T-cell co-inhibitory receptor PD-1. 
Depending on the balance of co-stimulatory and co-inhibitory ligands expressed on APCs 
a T cell can be either activated or suppressed.  
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APPENDIX II 
Cross-Presentation 
 Peptide antigens are presented to T cells either by major histocompatibility 
complex class I (MHC-I/recognized by CD8+ T cells) or class II (MHC-II/recognized by 
CD4+ T cells) molecules. MHC-II molecules are loaded with peptide fragments that 
derive from exogenous protein antigens (proteins that were endocytosed by the cell), 
while MHC-I molecules are traditionally loaded with peptide fragments that derive from 
endogenous protein antigens (cytosolic proteins). Cross-presentation is a useful 
mechanism that certain antigen-presenting cells (APC) use in order to present antigens of 
exogenous origin to CD8+ T cells. The mechanisms by which endocytosed proteins are 
processed and transferred to the MHC-I loading pathway are still unclear, but the end 
result is that exogenous peptide antigen is presented on MHC-I that can be recognized by 
CD8+ T cells. The practicality of cross-presentation is readily appreciated by the example 
of a non-virally infected cell. If a non-virally infected cell endocytoses exogenous viral 
particles, the normal chain of events would lead to presentation of viral peptide on MHC-
II molecules, which are only recognized by CD4+ T cells that cannot directly kill virally 
infected cells. By cross-presentation, processed viral-peptides are diverted to the MHC-I 
loading pathway so that viral peptides are presented on MHC-I to virus-specific CD8+ T 
cells capable of killing virally infected cells. Thus cross-presentation is an effective 
mechanism by which APCs activate CD8+ T cells using exogenously derived antigen.  
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